Were Analysts Bullish Merrimack Pharmaceuticals Inc (NASDAQ:MACK) This Week?

June 19, 2017 - By Marguerite Chambers

 Were Analysts Bullish Merrimack Pharmaceuticals Inc (NASDAQ:MACK) This Week?
Investors sentiment decreased to 0.9 in Q4 2016. Its down 0.17, from 1.07 in 2016Q3. It dropped, as 18 investors sold Merrimack Pharmaceuticals Inc shares while 40 reduced holdings. 21 funds opened positions while 31 raised stakes. 102.20 million shares or 3.48% more from 98.76 million shares in 2016Q3 were reported.
Boston Private Wealth Limited Liability Corporation reported 0.01% stake. Deutsche Bankshares Ag owns 1.38 million shares for 0% of their portfolio. Hsbc Hldgs Public Ltd Llc stated it has 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Voya Management Limited Liability Corporation has invested 0% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Pnc Svcs Group reported 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Schwab Charles Invest Mngmt Incorporated stated it has 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Lagoda Limited Partnership holds 2.13% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK) for 1.52 million shares. New York-based Consonance Management Limited Partnership has invested 4.06% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). 238,650 are held by Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Corporation. Blackrock Japan holds 0% or 2,847 shares. Moreover, Rhumbline Advisers has 0% invested in Merrimack Pharmaceuticals Inc (NASDAQ:MACK) for 135,885 shares. Stoneridge Prtn Limited Liability Co owns 221,838 shares. Blackrock holds 17,464 shares. Manufacturers Life Co The has invested 0% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Blackrock Institutional Na, a California-based fund reported 3.21 million shares.

Since May 12, 2017, it had 0 insider purchases, and 1 sale for $15,241 activity.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ratings Coverage

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals had 8 analyst reports since August 12, 2015 according to SRatingsIntel. Oppenheimer reinitiated the stock with “Outperform” rating in Wednesday, August 12 report. The firm earned “Buy” rating on Tuesday, August 11 by Brean Capital. As per Friday, May 27, the company rating was initiated by Robert W. Baird. The firm has “Outperform” rating given on Wednesday, August 12 by Mizuho. The rating was downgraded by JP Morgan to “Neutral” on Friday, October 7. The company was maintained on Tuesday, October 27 by Oppenheimer. The company was initiated on Friday, August 19 by BTIG Research. Mizuho maintained Merrimack Pharmaceuticals Inc (NASDAQ:MACK) on Wednesday, December 23 with “Buy” rating. Below is a list of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) latest ratings and price target changes.

About 1.35M shares traded. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has declined 44.78% since June 19, 2016 and is downtrending. It has underperformed by 61.48% the S&P500.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $149.06 million. The Firm is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. It currently has negative earnings. The Firm has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

More recent Merrimack Pharmaceuticals Inc (NASDAQ:MACK) news were published by: Streetinsider.com which released: “Merrimack Pharma (MACK) Completes Enrollment in Phase 2 CARRIE Study of MM-141 …” on June 19, 2017. Also Nasdaq.com published the news titled: “Merrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017” on May 26, 2017. Fool.com‘s news article titled: “Why Merrimack Pharmaceuticals Stock Is Tanking Today” with publication date: May 31, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.